Pancreatic Cancer Research

ResearcherUniversity of LiverpoolActive in the last 2 years

Christoph W. Michalski

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3520-1040; OpenAlex author ID A5089550509, A5108345968. Sources: OpenAlex.

Their work

Papers
80 (first author 8, last author 7)
Trials
0
Grants
0
Labs led
3
Collaborators
262
Papers, trials and grants by year

2011: 7 papers · 2012: 6 papers · 2013: 1 paper · 2014: 2 papers · 2015: 10 papers · 2016: 3 papers · 2017: 6 papers · 2018: 4 papers · 2019: 3 papers · 2020: 5 papers · 2021: 4 papers · 2022: 1 paper · 2023: none · 2024: 5 papers · 2025: 12 papers · 2026: 11 papers

Papers 50 of 80

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Arp2/3 complex and β1 integrin drive an invasive front through extracellular matrix adaptation in pancreatic cancer. Co-author DOI 10.1002/ijc.70376↗
  3. The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer. Last author DOI 10.1016/s1470-2045(25)00601-1↗
  4. Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. Co-author DOI 10.1038/s41388-026-04026-x↗
  5. New implications from long-term outcomes of perioperative therapy in resectable pancreatic cancer. Co-author DOI 10.1038/s41416-025-03295-9↗
  6. Pancreatic cancer. Last author DOI 10.1038/s41572-026-00699-6↗
  7. NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer. Co-author DOI 10.1093/jnci/djaf345↗
  8. A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
  9. Neoadjuvant therapy for left-sided resectable pancreatic ductal adenocarcinoma: evidence-based shift or premature extrapolation? Co-author DOI 10.21037/hbsn-2025-587↗
  10. Tumor Location and Preoperative Biliary Stenting Shape Gut Microbiome Diversity in Pancreatic Cancer. Co-author DOI 10.3390/cancers18162617↗
  11. Preoperative biliary stenting is associated with functional dysbiosis and impaired bile acid metabolism in pancreatic cancer - Impact of preoperative biliary s… Co-author DOI 10.64898/2026.05.19.719953↗
  12. ARP2/3 complex affects myofibroblast differentiation and migration in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.35246↗
  13. ChatGPT vs. surgeons on pancreatic cancer queries: accuracy & empathy evaluated by patients and experts. Co-author DOI 10.1016/j.hpb.2024.11.012↗
  14. Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. Co-author DOI 10.1016/j.xcrm.2024.101927↗
  15. ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. Co-author DOI 10.1038/s41388-025-03530-w↗
  16. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  17. Radical antegrade modular pancreatosplenectomy versus conventional left pancreatectomy for pancreatic cancer: study protocol for the multicentre randomized cli… Co-author DOI 10.1093/bjsopen/zraf169↗
  18. Erratum: The real-world management of advanced pancreatic cancer in China. First author DOI 10.1097/jp9.0000000000000220↗
  19. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  20. Pancreatic cancer patient-derived organoids capture therapy response and tumor evolution Co-author DOI 10.1101/2025.04.24.650216↗
  21. The role of the MicroBiome in PANCreatic cancer and its precursors- the study protocol of the MiBiPanc systematic review and meta-analysis. Co-author DOI 10.1186/s13643-025-02910-3↗
  22. Reply to: Adjuvant Treatment Options and Modalities in Pancreatic Adenocarcinoma: Insights From ESPAC4. Co-author DOI 10.1200/jco-25-00333↗
  23. Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Co-author DOI 10.1200/jco.24.01118↗
  24. [Sex differences in pancreatic cancer]. Co-author DOI 10.1007/s00104-024-02150-6↗
  25. Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response. Co-author DOI 10.1016/j.tranon.2024.102109↗
  26. A systemic look at pancreatic cancer patients: Predicting metastasis by studying the liver. First author DOI 10.1038/s41392-024-01964-4↗
  27. HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
  28. Intraoperative end-tidal carbon dioxide levels are not associated with recurrence-free survival after elective pancreatic cancer surgery: a retrospective cohor… Co-author DOI 10.3389/fmed.2024.1442283↗
  29. [Future concepts for neoadjuvant and adjuvant treatment of (resectable) pancreatic cancer]. First author DOI 10.1007/s00104-022-01623-w↗
  30. AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. Co-author DOI 10.1053/j.gastro.2021.07.030↗
  31. Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. Co-author DOI 10.1097/cej.0000000000000588↗
  32. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Co-author DOI 10.1136/gutjnl-2019-319990↗
  33. Pre-operative/Neoadjuvant Therapy and Vascular Debranching Followed by Resection for Locally Advanced Pancreatic Cancer (PREVADER): Clinical Feasibility Trial. First author DOI 10.3389/fmed.2021.588375↗
  34. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. Co-author DOI 10.1016/j.hpb.2019.06.012↗
  35. Precision oncology for pancreatic cancer in real-world settings. First author DOI 10.1016/s1470-2045(20)30148-0↗
  36. Surgery for synchronous and metachronous single-organ metastasis of pancreatic cancer: a SEER database analysis and systematic literature review. Co-author DOI 10.1038/s41598-020-61487-0↗
  37. CXCL10 and CCL21 Promote Migration of Pancreatic Cancer Cells Toward Sensory Neurons and Neural Remodeling in Tumors in Mice, Associated With Pain in Patients. Co-author DOI 10.1053/j.gastro.2020.04.037↗
  38. Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. Co-author DOI 10.1158/1055-9965.epi-19-1027↗
  39. Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. Co-author DOI 10.1002/ijc.31866↗
  40. Do we need sequential local therapy following neoadjuvant chemotherapy for locally advanced pancreatic cancer? Last author DOI 10.1016/j.eclinm.2019.11.015↗
  41. Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative ch… Co-author DOI 10.1136/bmjopen-2018-028696↗
  42. Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jcmgh.2018.07.003↗
  43. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Co-author DOI 10.1016/j.pan.2017.11.011↗
  44. Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. Co-author DOI 10.1093/ije/dyx269↗
  45. Response to the Letter to the Editor "Pancreatic Cancer and FOLFIRINOX: Should We Resect All Responders?" by Neoptolemos and Colleagues. First author DOI 10.1097/sla.0000000000002028↗
  46. Radical surgery of oligometastatic pancreatic cancer. Co-author DOI 10.1016/j.ejso.2016.10.023↗
  47. The TRIANGLE operation - radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study. Co-author DOI 10.1016/j.hpb.2017.07.007↗
  48. Targeting metabolism in pancreatic cancer. Co-author DOI 10.1016/s1470-2045(17)30304-2↗
  49. Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Co-author DOI 10.1136/gutjnl-2015-310442↗
  50. Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models. Co-author DOI 10.18632/oncotarget.15524↗

Closest collaborators

The 25 strongest of 262 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thilo Hackert · 18 shared papers, 2016–2026 · strength 2.84
  2. Jorg H. Kleeff · 40 shared papers, 2011–2025 · strength 2.79
  3. Bo Kong · 29 shared papers, 2011–2026 · strength 2.28
  4. Christoph Springfeld · 10 shared papers, 2016–2026 · strength 2.08
  5. Martin Loos · 9 shared papers, 2024–2026 · strength 1.96
  6. John P. Neoptolemos · 8 shared papers, 2013–2026 · strength 1.87
  7. Thomas P. Hank · 6 shared papers, 2025–2026 · strength 1.46
  8. Markus Wolfgang Büchler · 10 shared papers, 2016–2026 · strength 1.45
  9. Susanne Roth · 7 shared papers, 2019–2026 · strength 1.40
  10. Rosa Klotz · 5 shared papers, 2024–2025 · strength 1.36
  11. Chao Fang · 5 shared papers, 2025–2026 · strength 1.03
  12. Ingrid Herr · 5 shared papers, 2025–2026 · strength 1.03
  13. Helmut Frieß · 13 shared papers, 2011–2025 · strength 0.84
  14. Franco Fortunato · 4 shared papers, 2024–2026 · strength 0.83
  15. Helmut Friess · 12 shared papers, 2011–2026 · strength 0.83
  16. Christoph Kahlert · 4 shared papers, 2025–2026 · strength 0.82
  17. William Greenhalf · 9 shared papers, 2013–2026 · strength 0.78
  18. Eithne Costello · 9 shared papers, 2013–2026 · strength 0.78
  19. Núria Malats · 8 shared papers, 2017–2026 · strength 0.77
  20. Francisco X. Real · 8 shared papers, 2017–2026 · strength 0.77
  21. Max Heckler · 3 shared papers, 2026 · strength 0.69
  22. Daniel Öhlund · 2 shared papers, 2026 · strength 0.69
  23. Iréne Esposito · 12 shared papers, 2011–2026 · strength 0.68
  24. Ingmar Florin Rompen · 3 shared papers, 2025–2026 · strength 0.62
  25. Thomas Mathias Gress · 8 shared papers, 2015–2024 · strength 0.59

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.